Survey on understanding of MS treatment materials among healthcare professionals and patients
Survey Among Healthcare Professionals and MS Patients/Caregivers in Selected European Countries to Evaluate the Knowledge Required for the Safe Use of Mayzent
This study is trying to see how well healthcare professionals and patients understand educational materials about the MS treatment Mayzent to help improve those resources.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 335 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Novartis Industry-sponsored |
| Locations | 1 site (Basel) |
| Trial ID | NCT05301907 on ClinicalTrials.gov |
What this trial studies
This observational study involves a survey conducted among healthcare professionals, including neurologists and specialist nurses, as well as patients and caregivers dealing with Multiple Sclerosis (MS). The survey aims to assess the understanding and reception of educational materials related to the safety measures of Mayzent (siponimod). Participants from selected European countries and Canada will independently complete the survey to provide insights into their knowledge and experiences regarding MS treatment. The findings will help identify gaps in understanding and improve educational resources.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with relapsing MS who have been prescribed Mayzent (siponimod) for their treatment.
Not a fit: Patients who have not been initiated on Mayzent (siponimod) or do not have relapsing MS may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of MS treatment safety measures among healthcare providers and patients, leading to better patient outcomes.
How similar studies have performed: While this approach is observational and focuses on understanding educational materials, similar studies have shown that improving communication and education can significantly impact treatment adherence and outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Physicians will be considered eligible for the survey if they meet the following screening criteria: * Care for relapsing MS (RMS) patients * Personally prescribed disease modifying therapies to MS patients, and; * Have prescribed Mayzent (siponimod) in at least 1 SPMS patient. Nurses will be considered eligible for the survey if they: * Provide supportive care for RMS patients * Have initiated and/or managed the use of Mayzent (siponimod) in at least 1 SPMS patient. Patient inclusion criteria include: - Have been initiated onto Mayzent (siponimod) to treat their MS since reimbursement Exclusion Criteria: -
Where this trial is running
Basel
- Novartis Investigative Site — Basel, Switzerland (Recruiting)
Study contacts
- Study coordinator: Novartis Pharmaceuticals
- Email: novartis.email@novartis.com
- Phone: +41613241111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.